PD Dr. med. Dennis Kannenkeril
Oberarzt, Internist, Facharzt für Innere Medizin und Nephrologie, Zusatzbezeichnung Transplantationsmedizin, Hypertensiologe (DHL), ESH Clinical Hypertension Specialist

Einrichtungen
Medizin 4
Lebenslauf, Veröffentlichungen und Auszeichnungen
Publikationen
- (2026)PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease.Clin Res Cardiol. 2026;115(2): 220-231
- (2025)Predicting blood pressure response to renal denervation based on a new approach.J Hypertens. 2025;43(3): 413-419
- (2025)Response of Blood Pressure to Renal Denervation Is Not Associated With Genetic Variants.Hypertension. 2025;82(1): 118-125
- (2024)Skin sodium content as a predictor of blood pressure response to renal denervation.Hypertens Res. 2024;47(2): 361-371
- (2024)Is GFR decline induced by SGLT2 inhibitor of clinical importance?Cardiovasc Diabetol. 2024;23(1):
- (2024)Increase in Arterial Stiffness in Living Kidney Donors after Kidney DonationJ Am Soc Nephrol. 2024;35 Suppl S(10):
- (2024)Modification of Dialysate Na+ Concentration but not Ultrafiltration or Dialysis Treatment Time Affects Tissue Na+ Deposition in Patients on Hemodialysis.Kidney Int Rep. 2024;9(5): 1310-1320
- (2024)Renal adaptation in pre-obesity patients with hypertension.J Hypertens. 2024;42(11): 1958-1965
- (2024)Ultrasound-Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated TrialJ Am Coll Cardiol. 2024;84 Suppl S(18): B159-B159
- (2024)Sodium quantification in skeletal muscle: comparison between Cartesian gradient-echo and radial ultra-short echo time 23Na MRI techniques.Eur Radiol Exp. 2024;8(1):
- (2024)EFFECT OF RENAL DENERVATION ON BLOOD PRESSURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND UNCONTROLLED HYPERTENSION: RESULTS OF A PROSPECTIVE RANDOMIZED SHAM-CONTROLLED STUDYJ Hypertens. 2024;42 Suppl 1():
- (2024)Blood pressure reduction after renal denervation in patients with or without chronic kidney disease.Clin Kidney J. 2024;17(1):
- (2024)BLOOD PRESSURE RESPONDERS TO RENAL DENERVATION BASED ON A NEW DEFINITIONJ Hypertens. 2024;42 Suppl 1():
- (2024)Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.Circulation. 2024;149(10): 747-759
- (2024)WHY HAPPENS A PROGRESSIVE DECREASE OF BLOOD PRESSURE AFTER RENAL DENERVATIONJ Hypertens. 2024;42 Suppl 1():
- (2024)Renal Denervation Is Effective in Reducing Blood Pressure in Patients with CKD: Results of a Multicenter, Prospective, Randomized, Sham-Controlled, Blinded, Investigator-Initiated TrialJ Am Soc Nephrol. 2024;35 Suppl S(10):
- (2024)Relation between waist circumference and the renal hemodynamic in healthy individuals.Nutr Metab Cardiovasc Dis. 2024;34(3): 755-762
- (2024)36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO.Hypertens Res. 2024;47(12): 3467-3472
- (2024)INCREASE IN ARTERIAL STIFFNESS IN LIVING KIDNEY DONORS AFTER RENAL DONATIONJ Hypertens. 2024;42 Suppl 1():
- (2023)Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.JAMA. 2023;329(8): 651-661
- (2023)Is GFR decline induced by SGLT-2 inhibitor of clinical importance?Diabetologia. 2023;66 Suppl 1(SUPPL 1): S352-S352
- (2023)Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure.ESC Heart Fail. 2023;10(3): 1635-1642
- (2023)EFFECT OF PCSK9 INHIBITION WITH EVOLOCUMAB ON THE CONCENTRATION AND COMPOSITION OF LDL SUBFRACTIONS IN HIGH-RISK PATIENTS WITH CARDIOVASCULAR DISEASEAtherosclerosis. 2023;379 Suppl 1(): S71-S71
- (2023)RELATION BETWEEN WAIST CIRCUMFERENCE AND THE RENAL HEMODYNAMIC IN PATIENTS WITH UNCOMPLICATED HYPERTENSION GRADE 1-2J Hypertens. 2023;41 Suppl 3(): E264-E264
- (2023)RENAL DENERVATION REDUCES RETINAL ARTERIAL REMODELING IN PATIENTS WITH TREATMENT RESISTANT HYPERTENSION AND TYPE 2 DIABETES MELLITUSJ Hypertens. 2023;41 Suppl 3(): E296-E297
- (2023)SKIN SODIUM CONTENT AS A PREDICTOR OF BLOOD PRESSURE RESPONSE TO RENAL DENERVATIONJ Hypertens. 2023;41 Suppl 3(): E250-E251
- (2023)IS GFR DECLINE INDUCED BY SGLT-2 INHIBITOR OF CLINICAL IMPORTANCE?Nephrol Dial Transplant. 2023;38 Suppl 1(): I87-I88
- (2023)BLOOD PRESSURE REDUCTION AFTER RENAL DENERVATION IN PATIENTS WITH OR WITHOUT CHRONIC KIDNEY DISEASE: THE ERLANGER EXPERIENCEJ Hypertens. 2023;41 Suppl 3(): E256-E256
- (2023)PCSK-9-INHIBITOR THERAPY IMPROVES ENDOTHELIAL FUNCTION IN HIGH-RISK PATIENTS WITH CARDIOVASCULAR DISEASEJ Hypertens. 2023;41 Suppl 1(): E293-E293
- (2023)BLOOD PRESSURE REDUCTION AFTER RENAL DENERVATION IN PATIENTS WITH OR WITHOUT CHRONIC KIDNEY DISEASE: THE ERLANGER EXPERIENCEJ Hypertens. 2023;41 Suppl 1(): E484-E484
- (2023)The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial.Clin Res Cardiol. 2023;112(1): 134-144
- (2023)Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.J Am Coll Cardiol. 2023;82(19): 1809-1823
- (2023)Is vascular remodelling in patients with chronic heart failure exaggerated?ESC Heart Fail. 2023;10(1): 245-254
- (2023)Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis.Sci Rep. 2023;13(1):
- (2023)Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials.JAMA Cardiol. 2023;8(5): 464-473
- (2022)Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients.J Hum Hypertens. 2022;36(9): 811-818
- (2022)Evolocumab Alters Vascular Function in Patients With Cardiovascular DiseaseCirculation. 2022;146 Suppl 1():
- (2022)Retinal Capillary Damage Is Already Evident in Patients With Hypertension and Prediabetes and Associated With HbA1c Levels in the Nondiabetic Range.Diabetes Care. 2022;45(6): 1472-1475
- (2022)ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINEJ Hypertens. 2022;40 Suppl 1(SUPPL 1): E283-E284
- (2022)The influence of aircraft noise exposure on the systemic and renal haemodynamics.Eur J Prev Cardiol. 2022;29(1): 116-124
- (2022)IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIESJ Hypertens. 2022;40 Suppl 1(SUPPL): E59-E59
- (2022)SEMI-AUTOMATIC MEASUREMENT OF INTIMA-MEDIA THICKNESS OF BRACHIAL ARTERY IN PATIENTS WITH CONGESTIVE HEART FAILUREJ Hypertens. 2022;40 Suppl 1(SUPPL): E239-E239
- (2022)SEMI-AUTOMATIC MEASUREMENT OF INTIMA-MEDIA THICKNESS OF BRACHIAL ARTERY IN PATIENTS WITH CONGESTIVE HEART FAILUREJ Hypertens. 2022;40 Suppl 1(SUPPL): E239-E239
- (2022)IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIESJ Hypertens. 2022;40 Suppl 1(SUPPL): E59-E59
- (2022)DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILUREJ Hypertens. 2022;40 Suppl 1(SUPPL 1): E129-E129
- (2022)DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILUREJ Hypertens. 2022;40 Suppl 1(SUPPL): E129-E129
- (2022)Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.Cardiovasc Diabetol. 2022;21(1):
- (2022)Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study.Diabetol Metab Syndr. 2022;14(1):
- (2021)Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation.Hypertension. 2021;77(6): 1825-1844
- (2021)Increased pulse wave velocity in patients with an orthostatic blood pressure rise independent of other cardiovascular risk factors.J Hypertens. 2021;39(7): 1352-1360
- (2021)Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.Cardiovasc Diabetol. 2021;20(1):
- (2021)RELATION BETWEEN NOISE ANNOYANCE, STRESS HORMONES AND THE RENAL HEMODYNAMICJ Hypertens. 2021;39 Suppl 1(): E178-E178
- (2021)Association of Noise Annoyance with Measured Renal Hemodynamic Changes.Kidney Blood Press Res. 2021;46(3): 323-330
- (2021)ANNOYANCE DUE TO NOISE TRIGGERS VASCULAR CHANGES IN THE RENAL HEMODYNAMICJ Hypertens. 2021;39 Suppl 1(): E169-E169
- (2021)Microvascular changes at different stages of chronic kidney disease.J Clin Hypertens (Greenwich). 2021;23(2): 309-316
- (2021)LOW DOSE-EPLERENONE TREATMENT DECREASES AORTIC STIFFNESS IN PATIENTS WITH METABOLIC SYNDROMEJ Hypertens. 2021;39 Suppl 1(): E338-E338
- (2021)Supine blood pressure-A clinically relevant determinant of vascular target organ damage in hypertensive patients.J Clin Hypertens (Greenwich). 2021;23(1): 44-52
- (2021)Detection of Changes in Renal Blood Flow Using Arterial Spin Labeling MRI.Am J Nephrol. 2021;52(1): 69-75
- (2021)DETECTION OF CHANGES IN RENAL BLOOD FLOW USING ARTERIAL SPIN LABELING MRIJ Hypertens. 2021;39 Suppl 1(): E307-E307
- (2021)CAN WE IDENTIFY GLOMERULAR HYPERFILTRATION IN PATIENTS WITH TYPE 2 DIABETES BY CLINICAL PARAMETERS?J Hypertens. 2021;39 Suppl 1(): E211-E211
- (2021)Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozinEur Heart J. 2021;42 Suppl 1(): 795-795
- (2021)EFFECTS OF THE SGLT2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION IN PATIENTS WITH CHRONIC HEART FAILUREJ Am Coll Cardiol. 2021;77 Suppl 1(18): 1806-1806
- (2021)Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction.ESC Heart Fail. 2021;8(2): 1562-1570
- (2021)Dependency of flow-mediated vasodilatation from basal nitric oxide activity.Clin Physiol Funct Imaging. 2021;41(4): 310-316
- (2021)Effect of SGLT2 inhibition on ketone bodies in patients with stable chronic heart failureDiabetologia. 2021;64 Suppl 1(SUPPL 1): 107-107
- (2021)Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.Cardiovasc Diabetol. 2021;20(1):
- (2021)Angiotensin profiles in patients with type 2 diabetes and combination therapy of empagliflozin and linagliptin versus metformin and insulin glargineDiabetologia. 2021;64 Suppl 1(SUPPL 1): 256-256
- (2021)Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes.J Diabetes Complications. 2021;35(12):
- (2021)Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.ESC Heart Fail. 2021;8(6): 5327-5337
- (2021)Capillary vascular density in the retina of hypertensive patients is associated with a non-dipping pattern independent of mean ambulatory blood pressure.J Hypertens. 2021;39(9): 1826-1834
- (2021)THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILUREJ Am Coll Cardiol. 2021;77 Suppl 1(18): 585-585
- (2020)Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation.Am J Hypertens. 2020;33(2): 182-189
- (2020)Validation of semi-automated flow-mediated dilation measurement in healthy volunteers.Blood Press Monit. 2020;25(4): 216-223
- (2020)Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.Lancet. 2020;395(10234): 1444-1451
- (2020)Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.Eur Heart J Cardiovasc Pharmacother. 2020;6(6): 364-371
- (2020)Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography.Sci Rep. 2020;10(1):
- (2019)Evidence of neurodegeneration in individuals with only mildly elevated blood pressure.J Hypertens. 2019;37(12): 2389-2397
- (2019)How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.Cardiovasc Diabetol. 2019;18(1):
- (2019)Tissue sodium content in patients with type 2 diabetes mellitus.J Diabetes Complications. 2019;33(7): 485-489
- (2018)THE INFLUENCE OF ANNOYANCE DUE TO NOISE ON RENAL HEMODYNAMICJ Hypertens. 2018;36(): E39-E39
- (2018)DIFFERENT RESPONSE PATTERN TO AIRCRAFT NOISE EXPOSURE IN RENAL VERSUS SYSTEMIC HEMODYNAMICJ Hypertens. 2018;36(): E138-E138
- (2018)COPEPTIN AS A RESEARCH MARKER IN CARDIOVASCULAR DISEASEJ Hypertens. 2018;36(): E35-E35
- (2018)How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus?Eur Heart J. 2018;39(): 869-869
- (2018)SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.Cardiovasc Diabetol. 2018;17(1): 5
- (2018)EARLY VASCULAR PARAMETERS IN THE MICRO- AND MACROCIRCULATION IN TYPE 2 DIABETESJ Hypertens. 2018;36(): E9-E9
- (2018)Early vascular parameters in the micro- and macrocirculation in type 2 diabetes.Cardiovasc Diabetol. 2018;17(1):
- (2018)Retinal vascular resistance in arterial hypertension.Blood Press. 2018;27(2): 82-87
- (2017)Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.Circulation. 2017;136(12): 1167-1169
- (2016)Experience with belatacept rescue therapy in kidney transplant recipients.Transpl Int. 2016;29(11): 1184-1195
Sprechstunden
Nierentransplantationsvorbereitung (für Patientinnen und Patienten auf der Eurotransplant-Warteliste)
für Patientinnen und Patienten auf der Eurotransplant-Warteliste
Spezialsprechstunde
Dr. med. Katharina Heller
PD Dr. med. Dennis Kannenkeril
Zeiten
Montag bis Freitag nach Terminvereinbarung
Adresse
Internistisches Zentrum
Ulmenweg 18
91054 Erlangen
Raum
Transplantationszentrale D 00 718
Terminvergabe nur nach Absprache
Telefon: 09131 85-39195/-39196
Hinweis
In dieser Sprechstunde werden Patienten auf der Warteliste für die Nierentransplantation vorbereitet.
Mitzubringen
- Versicherungsnachweis (Krankenkassenkarte)
- Überweisungsschein Nr. 6 (an: Transplantationszentrale, Auftrag: Transplantationsgespräch)
- Überweisungsscheine Nr. 10 (an HLA-Labor, Auftrag: HLA-Typisierung, Bestimmung der HLA –Antikörper)
Bluthochdruck (schwer einstellbar) (Sprechstunde für Patientinnen und Patienten mit schwer einstellbarer arterieller Hypertonie und sekundären Formen der Hypertonie sowie Evaluation der Indikation zur renalen Denervation)
Sprechstunde für Patientinnen und Patienten mit schwer einstellbarer arterieller Hypertonie und sekundären Formen der Hypertonie sowie Evaluation der Indikation zur renalen Denervation
Spezialsprechstunde
Prof. Dr. med. Karl F. Hilgers
PD Dr. med. Dennis Kannenkeril
Terminvergabe nur nach Absprache
Hochschulambulanz
09131 85 - 32566
Montag - Freitag
11:00 - 15:00 Uhr
siehe "Hinweis"
Hinweis
In dieser Sprechstunde werden Patientinnen und Patienten mit schwer einstellbarer arterieller Hypertonie und sekundären Formen der Hypertonie behandelt. Die Indikation zur renalen Denervation wird evaluiert.
Für diese Sprechstunde ist eine vorherige Terminvereinbarung notwendig.
Wir bitten Sie, Ihren betreuenden Hausarzt oder Internisten, uns vorab folgende Unterlagen (soweit indiziert bzw. erhoben) per Fax (an 09131 85-33431) oder per Post zu schicken:
- Überweisungsschein vom Facharzt (Nephrologie, Innere Medizin, Kardiologie)
- ggf. Überweisungsschein für das Medizinische Labor Bremen (Urinscreening auf antihypertensive Substanzen)
- Medikamentenplan
- Blutwerte/Urinuntersuchung
- Blutbild
- Kalium, Natrium, Chlorid, Kreatinin, Harnstoff, Harnsäure, nüchtern bestimmte Blutfettwerte, nüchtern bestimmte Glucose
- TSH basal
- Aldosteron, Renin
- Urin-Albumin/Kreatinin-Verhältnis
- Ruhe-EKG
- 24h-Langzeit-Blutdruckmessung
- bisher vorliegende internistische Arztbriefe von ambulanten Vorstellungen/stationären Aufenthalten
Bitte denken Sie daran, Ihre Kontaktdaten bzw. die des Patienten anzugeben (Name, Adresse, Telefonnummer).
Diese Unterlagen werden dem zuständigen Oberarzt vorgelegt. Erst danach werden Sie zur Terminvereinbarung von uns angerufen oder angeschrieben.
Mitzubringen
- Versicherungsnachweis (Krankenkassenkarte)



